Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Other Operating Expenses (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Other Operating Expenses for 6 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 191.81% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2025, down 35.18% year-over-year, with the annual reading at $2.1 million for FY2025, 35.18% down from the prior year.
  • Other Operating Expenses hit $1.5 million in Q4 2025 for Lyell Immunopharma, down from $1.6 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $1.6 million in Q3 2025 to a low of -$1.1 million in Q2 2025.
  • Historically, Other Operating Expenses has averaged $766100.0 across 5 years, with a median of $778000.0 in 2021.
  • Biggest five-year swings in Other Operating Expenses: surged 425.11% in 2022 and later tumbled 208.81% in 2025.
  • Year by year, Other Operating Expenses stood at $798000.0 in 2021, then skyrocketed by 51.63% to $1.2 million in 2022, then plummeted by 47.02% to $641000.0 in 2023, then fell by 19.97% to $513000.0 in 2024, then surged by 191.81% to $1.5 million in 2025.
  • Business Quant data shows Other Operating Expenses for LYEL at $1.5 million in Q4 2025, $1.6 million in Q3 2025, and -$1.1 million in Q2 2025.